News

Most recently, Jacques served as Vice President of Healthcare Strategy, Partnerships & M&A at Microsoft.

The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the vision-threatening condition

LHON, a genetic disease that affects the retinal ganglion cells, results in severe bilateral sequential vision loss.

The potential gene therapy candidate is being evaluated for geographic atrophy.

The rationale was that commercial mydriatics administered during retinopathy of prematurity (ROP) screening have been associated with cardiorespiratory and gastrointestinal adverse events.

The trial is evaluating GAL-101 eye drops in patients with geographic atrophy, an advanced form of dry AMD.

In this study, researchers examine immune mechanisms in ocular diseases like uveitis, AMD, DR, and GO, highlighting microglial roles, targeted therapies, and promising advances in immunotherapy.

A look at the biggest news and advancements in ophthalmology in 2024.

This year was brimming with advancements in optometry.

A single lot (Lot 10101) of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count, is being voluntarily recalled by Alcon Laboratories due to the detection of fungal material in a consumer-reported vial.

Trending topics and milestone stories from 2024 on Ophthalmology Times Europe

A Helsinki University Hospital study found diabetes, glycemic control, or insulin therapy did not significantly affect anatomical or functional outcomes after epiretinal membrane surgery.

Let’s look back on some of the top stories on Modern Retina from 2024 as we gear up for an incredible 2025.

Did you miss any of our print issues this year? Don’t worry, they are still available online.

Curacle plans to finalize its development strategy, including phase 2b and 3 trials, through a Type C meeting with the US FDA in February of 2025.

The publication is entitled, “Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies.”

In the statement, the board calls attention to a proposal by a committee in the US House of Representatives that would shrink the National Institutes of Health’s (NIH) from 27 institutes into 15 institutes.

The European Commission will assess the marketing authorisation for Eydenzelt (reference product Eylea)

Espansione Group is known for photobiomodulation (PBM) technology – the Light Modulation Low-level Light Therapy (LLLT) along with the Intense Pulsed Light (IPL) technology.

The company is advancing its Phase I/II trial and exploring accelerated approval pathways in the US and Europe.

USC is leading a research team aiming to better understand retinitis pigmentosa and inform future treatments.

QUASAR is a global, double-masked, active-controlled phase 3 trial evaluating the efficacy and safety of EYLEA HD, compared to EYLEA, in patients with RVO, including those with central, branch and hemiretinal vein occlusions.

In the LIGHTHOUSE study, Atsena Therapeutics is evaluating ATSN-201 gene therapy for X-linked retinoschisis, leveraging AAV.SPR capsid for central retina transduction without foveal detachment risks.

The PFS is approved for treatment of neovascular age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion.

A global survey explores the impact of geographic atrophy (GA) on quality of life, revealing similar challenges for individuals with unilateral and bilateral GA.